SCHEMBL4489161

SCHEMBL4489161

O=C(O)c1cc2cc3c(cc2nc1Nc1cccc(Cl)c1)OCO3

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 13/20 0.49
CSNK2A2 P19784 11/20 0.49
CSNK2B P67870 11/20 0.49
MEN1 O00255 1/20 0.48
NPC1 O15118 1/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
MAPK1 P28482 1/20 0.48
RAB9A P51151 1/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
PIM1 P11309 3/20 0.47
PIM2 Q9P1W9 3/20 0.47
EGFR P00533 2/20 0.47
CHEK1 O14757 1/20 0.46
GAK O14976 1/20 0.46
DAPK3 O43293 1/20 0.46
DYRK3 O43781 1/20 0.46
ULK1 O75385 1/20 0.46
STK10 O94804 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5204584 0.82 CSNK2A1 (0.56) CSNK2A1CSNK2A2CSNK2BMEN1LMNA
SCHEMBL5202960 0.80 CSNK2A1 (0.61) CSNK2A1CSNK2A2CSNK2BMEN1NPC1
SCHEMBL4503390 0.79 PIM1 (0.55) CSNK2A1CSNK2A2CSNK2BMEN1KMT2A
SCHEMBL4489487 0.79 EGFR (0.61) CSNK2A1CSNK2A2CSNK2BMEN1LMNA
SCHEMBL5207731 0.78 ALDH1A1 (0.52) CSNK2A1CSNK2A2CSNK2BMEN1LMNA
SCHEMBL5205074 0.76 MEN1 (0.64) CSNK2A1CSNK2A2CSNK2BMEN1LMNA
SCHEMBL5204744 0.76 CSNK2A1 (0.49) CSNK2A1CSNK2A2CSNK2BMEN1LMNA
SCHEMBL5202883 0.76 CSNK2A1 (0.49) CSNK2A1CSNK2A2CSNK2BMEN1LMNA
SCHEMBL5207437 0.76 MEN1 (0.64) CSNK2A1CSNK2A2CSNK2BMEN1LMNA
SCHEMBL5204702 0.75 CSNK2A1 (0.48) CSNK2A1CSNK2A2CSNK2BMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482455-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-01-27 US claimed
EP-1556379-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-13 EP claimed
US-20060106058-A1 Chemical compounds BURGESS JOELLE L 2006-05-18 US claimed
EP-1556379-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-07-27 EP claimed
WO-2004034985-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO claimed
US-7482455-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-01-27 US disclosed
EP-1556379-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-13 EP disclosed
US-20060106058-A1 Chemical compounds BURGESS JOELLE L 2006-05-18 US disclosed
EP-1556379-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-07-27 EP disclosed
WO-2004034985-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106058-A1 Chemical compounds YARS1, DAPK3, NEK3 CSNK2A1 248/4885CSNK2A2 239/4885CSNK2B 308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.